Veradermics Presents New Phase 2/3 Data Highlighting the Potential of VDPHL01 for Male Pattern Hair Loss Across Age Groups
Veradermics, Incorporated, a late-stage biopharmaceutical company founded by dermatologists and dedicated to developing innovative therapies for pattern hair loss, has announced the presentation of new clinical data from its Phase 2/3 Study ‘302’ evaluating VDPHL01, the company’s investigational extended-release oral minoxidil formulation. The findings were presented during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City and provide additional insight into the therapy’s efficacy and safety across different age groups of men with mild-to-moderate pattern hair loss.
The newly released results stem from an age-based subgroup analysis involving male participants younger than 40 years and those aged 40 years and older. The analysis is intended to help researchers better understand whether patient age influences treatment response and safety outcomes, supporting the broader clinical development of VDPHL01 as a potential oral treatment for androgenetic alopecia, commonly known as pattern hair loss.
The data were initially showcased in a scientific poster presentation on July 16, 2026, and were scheduled for further discussion in an oral presentation on July 17, 2026, during one of dermatology’s leading scientific meetings.
Addressing a Common Yet Challenging Condition
Pattern hair loss is the most prevalent cause of hair thinning among men, affecting millions worldwide. The condition is progressive and typically begins with recession of the frontal hairline and thinning at the crown before advancing over time. Although not life-threatening, hair loss can significantly affect self-confidence, emotional well-being, and quality of life.
Current treatment options are limited, with many patients relying on topical formulations, oral medications prescribed off-label, or hair restoration procedures. While topical minoxidil has long been a standard treatment, maintaining consistent application can be difficult for many patients, leading researchers to explore more convenient oral alternatives.
Veradermics is seeking to address this unmet need by developing VDPHL01, a proprietary extended-release oral formulation of minoxidil designed to provide sustained drug delivery while potentially improving patient adherence and treatment outcomes.
About the Phase 2/3 Study ‘302’
Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating the efficacy and safety of VDPHL01 in more than 500 male participants with mild-to-moderate pattern hair loss.
The study was designed to compare treatment with the investigational therapy against placebo while assessing improvements in hair growth, overall scalp appearance, and safety over the course of treatment.
Randomization and blinding ensured that neither participants nor investigators knew which treatment each patient received, helping minimize bias and strengthen the reliability of the study findings.
The trial represents one of the key components of Veradermics’ late-stage clinical development program aimed at securing regulatory approval for VDPHL01.
New Age-Based Subgroup Analysis
The latest analysis focused on determining whether treatment outcomes differed according to patient age.
Investigators divided study participants into two predefined groups:
- Men younger than 40 years of age
- Men aged 40 years and older
Age can influence the progression of androgenetic alopecia, the extent of follicular miniaturization, and treatment responsiveness. By evaluating these groups separately, researchers hoped to determine whether VDPHL01 demonstrates consistent performance across different stages of disease progression.
Although the company did not disclose detailed numerical outcomes in the announcement, the subgroup analysis examined both:
- Treatment efficacy
- Overall safety and tolerability
Understanding these differences is particularly important because pattern hair loss often begins in early adulthood but progresses throughout middle age and beyond.
A therapy capable of providing meaningful benefit across a broad age range could become an attractive treatment option for many patients seeking convenient long-term management.
Extended-Release Oral Minoxidil
Minoxidil has been used for decades as a treatment for pattern hair loss, most commonly in topical formulations applied directly to the scalp.
More recently, low-dose oral minoxidil has attracted increasing attention among dermatologists because of its potential to improve hair growth without requiring daily topical application.
VDPHL01 has been specifically engineered as an extended-release oral tablet, allowing the medication to be released gradually over time rather than immediately after administration.
This controlled-release technology is intended to:
- Maintain more consistent drug levels
- Improve patient convenience
- Support once-daily dosing
- Potentially enhance tolerability
- Encourage long-term treatment adherence
Because pattern hair loss requires continuous treatment to maintain benefits, patient compliance remains one of the most important factors influencing therapeutic success.
An effective oral therapy with a favorable safety profile could provide a valuable alternative for individuals who struggle with topical treatments.
Building on Earlier Positive Results
The subgroup findings presented at the AAD Innovation Academy build upon topline results that Veradermics announced earlier in April 2026.
Those earlier results from Study ‘302’ demonstrated encouraging efficacy and safety outcomes in men with mild-to-moderate pattern hair loss, supporting continued advancement of the development program.
The newly presented age-specific analysis provides additional evidence that may help physicians better understand which patient populations could benefit most from treatment.
Subgroup analyses are commonly conducted during late-stage clinical development to evaluate consistency of treatment effects across various demographic and clinical characteristics.
Expanding a Comprehensive Clinical Development Program
Veradermics is conducting one of the industry’s more comprehensive development programs focused exclusively on pattern hair loss.
Rather than limiting evaluation to a single patient population, the company is simultaneously investigating VDPHL01 in both men and women.
Male Pattern Hair Loss Program
The male clinical development program currently includes multiple late-stage studies.
Earlier this year, Veradermics announced completion of patient enrollment in Study ‘304’, its second Phase 3 clinical trial involving male patients with pattern hair loss.
Topline data from this study are expected during the second half of 2026.
The availability of results from two large late-stage studies could strengthen the evidence supporting future regulatory submissions.
Female Pattern Hair Loss Studies
In addition to the male program, Veradermics is also evaluating VDPHL01 for women experiencing pattern hair loss.
Earlier in the same week as the AAD Innovation Academy presentations, the company announced positive topline data from Study ‘207’, which evaluated female participants.
Meanwhile, Study ‘306’, a registration-directed Phase 2/3 clinical trial in women, continues to progress.
Topline results from that study are anticipated during the first half of 2027.
By conducting parallel development programs for both sexes, Veradermics aims to broaden the potential clinical applications of VDPHL01 while addressing the significant unmet needs associated with hair loss in both men and women.
Scientific Presentation at AAD Innovation Academy
The new subgroup analysis was presented by Dr. Maria Hordinsky, a board-certified dermatologist and internationally recognized expert in hair disorders.
Dr. Hordinsky serves as the R.W. Goltz Professor and Vice Chair of Research in the Department of Dermatology at the University of Minnesota Twin Cities and has participated as an investigator in the Veradermics clinical program.
Her oral presentation focused on the efficacy and safety of VDPHL01 across different age groups and highlighted the importance of understanding treatment responses among patients at varying stages of hair loss progression.
Presenting these findings at the AAD Innovation Academy allows researchers and clinicians to evaluate the latest evidence while discussing potential implications for future dermatologic practice.
Importance of Innovation in Hair Loss Treatment
Pattern hair loss remains one of the most common reasons patients seek dermatologic care, yet treatment innovation has progressed relatively slowly compared with many other dermatology specialties.
Although existing therapies can slow disease progression and stimulate hair growth in some individuals, response rates vary considerably, and long-term adherence remains a persistent challenge.
The development of extended-release oral therapies represents one potential strategy for improving convenience while maintaining efficacy.
If successful, VDPHL01 could expand treatment options by providing patients with a prescription oral medication specifically developed for pattern hair loss rather than relying on formulations originally designed for other medical conditions.
Veradermics continues to advance VDPHL01 through an extensive late-stage clinical development program designed to support regulatory approval for both male and female pattern hair loss. The latest subgroup analysis from Phase 2/3 Study ‘302’ adds to the growing body of evidence supporting the investigational therapy, demonstrating its evaluation across different age groups while reinforcing the company’s commitment to understanding treatment performance in diverse patient populations.
With additional Phase 3 results expected later in 2026 and ongoing registration-directed studies in women continuing into 2027, Veradermics is steadily building the clinical evidence required to support future regulatory submissions. If the ongoing studies confirm the promising results observed to date, VDPHL01 could emerge as an important new oral treatment option for millions of individuals living with pattern hair loss, offering a convenient extended-release approach designed to improve both treatment adherence and long-term hair restoration outcomes.
About VDPHL01
VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, oral non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption.
VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01. The earliest expiring patent term is 2043.
About Pattern Hair Loss
Pattern hair loss, also known as androgenetic alopecia, affects an estimated 80 million people in the United States (30 million women and 50 million men). Pattern hair loss can have a significant impact on quality of life, affecting an individual’s mental health and relationships. People with pattern hair loss often experience depression, low self-esteem, and social withdrawal.
There have been no new FDA-approved prescription medicines for pattern hair loss in nearly 30 years. In addition, current treatments include over-the-counter “nutraceuticals” that produce inconsistent results and contribute to high dissatisfaction among participants and healthcare providers. The prevalence of pattern hair loss and the market demand for new treatments contribute to making it the largest aesthetics market worldwide, projected to reach approximately $30 billion by 2028.
About Veradermics, Inc.
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, with potential selective development of medical dermatology product candidates.
Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss, to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform pattern hair loss treatment. VDPHL01 is an oral, extended-release proprietary formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity.